Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT04603040Phase 2Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Sep 2020; status: terminated.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04603040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603040.